10 th Annual ENETS Conference

Size: px

Start display at page:

Download "10 th Annual ENETS Conference"

Domenic Barnett
5 years ago
Views:

1 10 th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease 6-8 March 2013 Barcelona P R E L I M I N A R Y P R O G R A M 1

2 Scientific Organizing Committee Martyn Caplin, London, United Kingdom Massimo Falconi, Torette-Ancona, Italy Beata Kos-Kudła, Katowice, Poland Kjell Öberg, Uppsala, Sweden Dermot O Toole, Dublin, Ireland Aurel Perren, Bern, Switzerland Philippe Ruszniewski, Clichy, France Ramon Salazar, Barcelona, Spain Bertram Wiedenmann, Berlin, Germany Conference Organization ENETS Office c/o Charité Universitätsmedizin Campus Virchow-Klinikum Hepatology and Gastroenterology Augustenburger Platz 1 D Berlin, Germany Tel.: (general information); (hotels) Fax: ENETS-annual-conference@charite.de Conference Venue El Centro de Convenciones Internacional de Barcelona (CCIB) Plaça de Willy Brandt, Barcelona t f REGISTRATION and MATERIAL PICK-UP: Conference registration (conference material pick-up) will take place at the entrance area of the CCIB, on the ground floor. Registration begins on Tuesday, 5 March 2013, from 2:00 p.m. until 6:00 p.m. Early pick-up continues on Wednesday, 6 March, at 7:30 a.m. and runs until 5:30 p.m. The registration area will remain open on Thursday and Friday, from 7:30 a.m. until 6:00 p.m. In addition, the ENETS Office will be open from Wednesday until Friday, from 8:00 a.m. until 6:00 p.m. 2

3 ENETS POST-GRADUATE COURSE Wednesday, 6 March 2013, Room TBA Prior online registration and payment ( 100 per participant pre-meeting registration; 150 on-site registration) required 8:15 9:15 Registration and coffee 9:15 9:35 Introduction and overview M. Caplin, London, United Kingdom 9:35 9:55 Role of TNM staging in NET management U.-F. Pape, Berlin, Germany 9:55-10:15 Biomarkers for NETs: the future K. Öberg, Uppsala, Sweden 10:15-10:30 Discussion 10:30 10:50 ENETS clinical case 1: Rectum J. Ramage, Basingstoke, United Kingdom 10:50 11:20 Coffee break 11:20 11:40 When should EUS be used in NETs D. O Toole, Dublin, Ireland 11:40 12:00 New PET agents v. OctreoScan: which to use and why A. Sundin, Stockholm, Sweden 12:00 12:15 Discussion 12:15 12:40 ENETS clinical case 2: Pancreas with long survival R. Kianmanesh, Reims, France 12:40 14:10 Lunch 14:10 14:30 Chemotherapy v. molecular targeted therapy for pancreatic NET R. Salazar, Barcelona, Spain 14:30 14:50 Chemotherapy v. molecular targeted therapy for intestinal NET M. Pavel, Berlin, Germany 14:50 15:10 MIBG, Y-90 DOTATOC / TATE to Lutetium-177 DOTA Octreotate Evolution and survival of the fittest J. Cwikla, Warsaw, Poland 15:10 15:20 Transarterial embolisation v. chemoembolisation: which is better? P. Ruszniewski, Clichy, France 15:20 15:35 Discussion 15:35 15:55 Coffee break 15:55 16:15 ENETS clinical case 3: CUP A. Grossman, London, United Kingdom 16:15 16:35 Laparoscopic surgery for NET when is it appropriate? M. Falconi, Torette- Ancona, Italy 16:35 16:55 How to manage gastrointestinal complications in NETs B. Wiedenmann, Berlin, Germany 16:55 17:10 Discussion 17:10 17:15 Close M. Caplin, London, United Kingdom 3

4 17:30 18:00 Keynote Address Prof. Kjell Öberg, ENETS Chairman Neuroendocrine Tumors: From Eminence to Evidence-Based Medicine, a 30-Year Journey (Welcome Reception to follow, Second Floor, Banquet Hall) Thursday, 7 March 2013 Meet the Professor Limited entrance; prior online registration required, 20 per participant. All sessions held on the first floor. Breakfast will be served. 7:30 8:30 a.m. Mixed Adenoneuroendocrine Carcinoma (Room 127) (Sponsored by Lexicon) M. Volante, Turin, Italy Lifelong with NET (Room 128) (Sponsored by Novartis) J. Ramage, Basingstoke, United Kingdom Medullary thyroid carcinoma (Room 129) (Sponsored by Novartis) G. Kaltsas, Athens, Greece Inherited NETs (Room 130) (Sponsored by Novartis) W. de Herder, Rotterdam, The Netherlands Difficult pathological cases (Room 131) (Sponsored by Novartis) A. Perren, Bern, Switzerland How do I perform a middle pancreatectomy and enucleation? (Room 132) P. Jagannath, Mumbai, India P L E N A R Y S E S S I O N (First Floor, Rooms ) 8:45 8:50 a.m. Welcome and Introduction K. Öberg, Uppsala, Sweden; Ramon Salazar, Barcelona, Spain 8:50 10:00 a.m. SESSION 1: Histopathology today Chairs: D. O Toole, Dublin, Ireland; A. Perren, Bern, Switzerland 9:50 9:05 a.m. Grading NETs: Is it easy? J.-Y. Scoazec, Lyon, France 9:05 9:20 a.m. How do we evaluate Ki-67? G. Rindi, Rome, Italy 9:20 9:35 a.m. Is histopathology more than morphology? L. Tang, New York, NY, USA 9:35 9:50 a.m. What s in it for the clinician? F. Panzuto, Rome, Italy 9:50 10:00 a.m. Discussion 4

5 10:00 10:30 a.m ENETS Life Achievement Award Recipient and keynote presentation: Larry Kvols, Tampa, FLA, USA Dedication: Jonathan Strosberg, Tampa, FLA, USA Chair: K. Öberg, Uppsala, Sweden 10:30 11:00 a.m. Hot news in clinical trials M. Pavel, Berlin, Germany 11:00 11:30 a.m. COFFEE BREAK and POSTER VIEWING (Ground floor) 11:30 a.m. 12:30 p.m. SESSION 2A: BASIC SCIENCE ABSTRACTS Rooms 111 & 112 Chairs: J. Capdevila; Barcelona, Spain; A. Scarpa, Verona, Italy 11:30 11:40 a.m. A Novel Animal Model For Medullary Thyroid Carcinoma K. Pozo, Dallas, TX, USA 11:40 11:50 a.m. Whole Exome Sequence Of BON-1 And QGP-1, Two Human Pancreatic Neuroendocrine Tumor Cell Lines, Reveals Homozygous Loss Of Function Mutations In TP53, HRNR and CYFIP2 T. Vandamme, Wilrijk, Belgium 11:30 a.m. 12:30 p.m. SESSION 2B: RARE TUMORS Chairs: W. de Herder, Rotterdam, The Netherlands; D. Ferone, Genoa, Italy 11:30 11:50 a.m. Paraganglioma E. Corssmit, Leiden, The Netherlands 11:50 12:10 p.m. Merkel Cell Tumors J. Becker, Graz, Austria 12:10 12:30 p.m. Thymic NET P. Ferolla, Perugia, Italy 11:50 12:00 p.m. Isolation and Whole Genome Amplification of Single Circulating Tumor Cells in Neuroendocrine Tumors: A Pilot Study D. Mandair, London, United Kingdom 12:00 12:10 p.m. Comparative Expression Analysis of Chromosome 18 Related mirnas in Ileal NET With and Without Chr18 Loss J. Sperveslage, Tübingen, Germany 12:10 12:20 p.m. Olfactory Receptor 51E1 is a Potential Novel Target for Diagnosis and Treatment of Somatostatin Receptor Negative Lung Carcinoid Patients T. Cui, Uppsala, Sweden 12:20 12:30 p.m. DISCUSSION 12:30 2:00 p.m. LUNCH and SYMPOSIUM I, sponsored by Pfizer: Learning from experience with targeted therapies in progressive pancreatic NET (Symposium in Rooms 111 and 112, First Floor) 5

6 2:30 4:00 p.m. SESSION 3A: LUNG NETS: TOWARDS ENETS GUIDELINES Rooms 111 & 112 Chairs: M. Caplin, London, United Kingdom; J. O Connor, Buenos Aires, Argentina 2:30 2:50 p.m. Histopathology and classification G. Pelosi, Milan, Italy 2:50 3:10 p.m. Clinical presentation and diagnostics M. Caplin, London, United Kingdom 3:10 3:30 p.m. Medical therapy E. Baudin, Villejuif, France 3:30 3:50 p.m. Surgery E. Lim, London, United Kingdom 2:30 4:00 p.m. SESSION 3B: NEW STRATEGIES IN NET TARGETING Chairs: M. Kulke, Boston, MA, USA; B. Wiedenmann, Berlin, Germany 2:30 2:50 p.m. PK1-mTOR pathways N. Sonenberg, Montreal, Canada 2:50 3:10 p.m. G-protein coupled receptors J.C. Reubi, Bern, Switzerland 3:10 3:30 p.m. Epigenetics A. Meeker, Baltimore, MD, USA 3:30 3:50 p.m. Oncolytic viruses M. Essand, Uppsala, Sweden 4:00 4:30 p.m. COFFEE BREAK and POSTER VIEWING (Ground Floor) 4:30 5:30 p.m. ENETS GENERAL ASSEMBLY (For ENETS Members Only) 5:30 7:00 p.m. SYMPOSIUM II, sponsored by Novartis (Symposium in Rooms 111 and 112, First Floor) Friday, 8 March 2013 Meet the Professor Limited entrance; prior online registration required, 20 per participant. All sessions held on the first floor. Breakfast will be served. 7:30 8:30 a.m. Mixed Adenoneuroendocrine Carcinoma (Room 127) (Sponsored by Pfizer) M. Volante, Turin, Italy Lifelong with NET (Room 128) (Sponsored by Pfizer) J. Ramage, Basingstoke, United Kingdom Medullary thyroid carcinoma (Room 129) (Sponsored by Pfizer) G. Kaltsas, Athens, Greece Inherited NETs (Room 130) (Sponsored by Ipsen) W. de Herder, Rotterdam, The Netherlands Difficult pathological cases (Room 131) (Sponsored by Ipsen) A. Perren, Bern, Switzerland How do I perform a middle pancreatectomy and enucleation? (Room 132) P. Jagannath, Mumbai, India 6

7 P L E N A R Y S E S S I O N (First Floor, Rooms ) 8:30 10:00 a.m. SESSION 4: Does surgery improve outcome in GEP-NETs? Chairs: R. Jensen, Bethesda, MD, USA; A. Frilling, London, United Kingdom 8:30 8:50 a.m. What is standard but not evidence-based? M. Falconi, Verona, Italy 8:50 9:15 a.m. Surveillance v. surgery for small pnets A. Sauvanet, Clichy, France (20 min.) D. Bartsch, Marburg, Germany (5 min. rebuttal) 9:15 9:40 a.m. Limited v. standard or oncological resection B. Niederle, Vienna, Austria (limited) U. Knigge, Copenhagen, Denmark (standard) 9:40 10:00 a.m. Lessons from EHBPA A. Frilling, London, United Kingdom 10:00 10:30 a.m. Towards new criteria in evaluating tumor response to treatment A. Grossman, London, United Kingdom 10:30 11:00 a.m. COFFEE BREAK and POSTER VIEWING (Ground Floor) 11:00 a.m. 12 noon SESSION 5A: CLINICAL ABSTRACTS Chairs: D. Gross, Jerusalem, Israel; E. Sedlackova, Prague, Czech Republic 11:00 11:10 a.m. Long-Term Follow-Up of MEN-1 Patients With Non-Operated Small <2cm Non-Functional Neuroendocrine Tumor of the Pancreas (NF- PET) F. Triponez, Geneva, Switzerland 11:10 11:20 a.m. Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients With Carcinoid Syndrome: Results of a Phase 2, Multicenter, Open-Label, Serial-Ascending Study M. Pavel, Berlin, Germany 11:20 11:30 a.m. O6-Methylguanine-DNA Methyltransferase Deficiency in Neuroendocrine Tumors and Correlation With Response to Alkylating Agents (Temozolomide, Streptozotocin, Dacarbazine) T. Walter, Lyon, France 11:30 11:40 a.m. Risk of Recurrence in Patients with Neuroendocrine Tumors After R0-Resection 11:00 a.m. 12 noon SESSION 5B: SESSION 5B: KEY ISSUES WITH APPENDICEAL AND RECTAL NETS Rooms 111 & 112 Chairs: A. Couvelard, Clichy, France; G. Delle Fave, Rome, Italy 11:00 11:20 a.m. Neuroendocrine v. goblet cell appendiceal tumors: the need to distinguish M. Papotti, Turin, Italy 11:20 11:40 a.m. What should be done after removal of an appendiceal NET or goblet cell tumors? T. Steinmüller, Berlin, Germany 11:40 12 noon Do small rectal NETs matter what to do? A. Pascher, Berlin, Germany 7

8 A. Rinke, Marburg, Germany 11:40 11:50 a.m. Neoadjuvant Treatment of Non-Functioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate E. I. Van Vliet, Rotterdam, The Netherlands 11:50 a.m. 12 noon DISCUSSION 12 noon 12:30 p.m. POSTER DISCUSSION 12:30 2:00 p.m. LUNCH and SYMPOSIUM III, sponsored by Ipsen (Symposium in Rooms 111 and 112, First Floor) 2:00 3:00 p.m. SESSION 6: Controversies in well-differentiated NETs Chairs: P. Ruszniewski, Clichy, France; B. Kos-Kudla, Katowice, Poland Active Treatment or wait-and-see approach in stage 4 welldifferentiated NETs PRO CON S. Glasberg, Jerusalem, Israel R. Salazar, Barcelona, Spain Should FDG-PET be performed in well-differentiated NETs PRO CON T. Meyer, London, United Kingdom E. Krenning, Rotterdam, The Netherlands 3:00 3:15 p.m. Best Abstracts of :15 4:15 p.m. SESSION 7: CLINICAL CASES FROM THE ENETS ADVISORY BOARD 3:15 3:35 p.m. ACTH R. Jensen, Bethesda, MD, USA 3:35 3:55 p.m. MTC J. Capdevila, Barcelona, Spain 3:55 4:15 p.m. Lung D. Gross, Jerusalem, Israel END OF MEETING 8

Preliminary Conference Program

Preliminary Conference Program Contents Scientific Organizing Committee... 1 ENETS Scientific Conference Program... 2 09.03.2016... 2 ENETS Postgraduate Course... 2 Welcome Reception... 3 10.03.2016...